Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Salah U. Qureshi is active.

Publication


Featured researches published by Salah U. Qureshi.


Psychiatric Quarterly | 2009

The Link Between Post-traumatic Stress Disorder and Physical Comorbidities: A Systematic Review

Salah U. Qureshi; Jeffrey M. Pyne; Kathy M. Magruder; Paul E. Schulz; Mark E. Kunik

Context Returning veterans from Afghanistan and Iraq will increase frequency of post-traumatic stress disorder (PTSD). Little is known about its impact on physical health. Objective Systematic literature review focusing on the association between PTSD and specific physical disorders. Data Sources An electronic search using PUBMED and hand search of four journals with an anxiety focus for studies published between January 1981 and July 2008, plus a manual search of article bibliographies. Study Selection Original research reports focusing on PTSD and its association with physical health. Studies investigating only PTSD symptoms, trauma and physical disorders classified at the organ-system level were excluded. Eighty studies were reviewed and seven selected for final analysis. Data Extraction Specific physical-health diagnoses were organized by system and tabulated. They were considered positive only if results were statistically significant. Total number of positive and negative studies for each diagnosis was then calculated for review. Results Seven studies examined the relationship between PTSD and specific physical disorders. Arthritis was associated with PTSD in most studies. Data conflicted regarding diabetes, coronary heart disease, and stroke. Conclusions Few studies have examined the relationship between PTSD and physical health. Large, prospective epidemiological trials are needed.


American Journal of Geriatric Pharmacotherapy | 2009

Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review

Kairav Shah; Salah U. Qureshi; Michael L. Johnson; Niraj Parikh; Paul E. Schulz; Mark E. Kunik

BACKGROUND Hypertension appears to contribute to the development of dementia. Antihypertensive drugs may play an important role in altering the incidence or progression of dementia, particularly dementia of the vascular type; however, the neuroprotective effects of these agents in other types of dementia are not well characterized. OBJECTIVES The main aims of this review were to examine the relationship between use of antihypertensive agents and the incidence and progression of Alzheimers dementia (AD), vascular dementia (VaD), and unspecified dementia, and to consider whether these agents may be neuroprotective. METHODS A search of the English-language literature (January 1996-August 2009) was conducted using PubMed, Ovid MEDLINE, EBSCO MEDLINE, and the Cochrane Database of Systematic Reviews for publications mentioning both antihypertensive drugs and dementia. A combination of searches was performed using the following terms: antihypertensive drugs, dementia, cognitive impairment, Alzheimers dementia, vascular dementia, progression of cognitive impairment, severity of cognitive impairment, severity of dementia, prevalence, and incidence. Searches were also performed using the names of antihypertensive drug classes. The bibliographies of all retrieved articles were reviewed for additional relevant publications. The focus was on randomized controlled trials, cohort studies, and case-control studies, excluding studies in animals, patients aged <45 years, drugs other than antihypertensive agents, and the role in cognition of hormones, receptors, and enzymes. RESULTS Sixty-five potentially relevant articles were identified from the 536 publications retrieved by the literature search. After application of the exclusion criteria, 12 original studies were included in the review, all published between 1999 and 2008 and most involving patients with AD or VaD. The most frequently studied antihypertensive agents were calcium channel blockers (7 studies), diuretics (6 studies), and angiotensin-converting enzyme (ACE) inhibitors (6 studies). Overall, these medications appeared to be beneficial in dementia, but only ACE inhibitors and diuretics significantly reduced the risk for and progression of dementia in the majority of studies. CONCLUSIONS Antihypertensive medications-particularly ACE inhibitors and diuretics-may be helpful in reducing the risk for and progression of dementia. Large randomized clinical trials are warranted to further explore the relationship between antihypertensive drugs and dementia.


Journal of the American Geriatrics Society | 2010

Greater Prevalence and Incidence of Dementia in Older Veterans with Posttraumatic Stress Disorder

Salah U. Qureshi; Timothy Kimbrell; Jeffrey M. Pyne; Kathy M. Magruder; Teresa J. Hudson; Nancy J. Petersen; Hong Jen Yu; Paul E. Schulz; Mark E. Kunik

To explore the association between posttraumatic stress disorder (PTSD) and dementia in older veterans.


Journal of Neuropsychiatry and Clinical Neurosciences | 2011

Does PTSD impair Cognition beyond the effect of Trauma

Salah U. Qureshi; Mary E. Long; Major R. Bradshaw; Jeffrey M. Pyne; Kathy M. Magruder; Timothy Kimbrell; Teresa J. Hudson; Ali Jawaid; Paul E. Schulz; Mark E. Kunik

This systematic review analyzed data from studies examining memory and cognitive function in subjects with posttraumatic stress disorder (PTSD), compared with subjects exposed to trauma (but without PTSD). Based on analysis of 21 articles published in English from 1968 to 2009, the conclusion is that individuals with PTSD, particularly veterans, show signs of cognitive impairment when tested with neuropsychological instruments, more so than individuals exposed to trauma who do not have PTSD.


Amyotrophic Lateral Sclerosis | 2010

A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS

Ali Jawaid; Santosh B. Murthy; Andrew M. Wilson; Salah U. Qureshi; Moath J. Amro; Michael Wheaton; Ericka Simpson; Yadollah Harati; Adriana M. Strutt; Michele K. York; Paul E. Schulz

Abstract Our objective was to test the hypothesis that changes in body mass index (BMI) are associated with changes in the clinical course of ALS. We examined the relationships between BMI at first clinical visit and changes in BMI up to a two-year follow-up, and multiple clinical variables related to ALS: age of onset, rate of progression of motor symptoms, and survival. Baseline BMI was classified according to the World Health Organization (WHO) criteria. Changes in BMI were classified as a loss of >1 unit, no change, or a gain of >1 unit. Our results showed that baseline BMI was not associated with age of onset, rate of progression or survival. In contrast, a loss of BMI >1 over two years was associated with significantly shorter survival and a faster rate of progression. In a multiple regression model, these results were independent of gender, site of onset, history of diabetes mellitus and apolipoprotein (ApoE) genotype. In summary, a change in BMI after ALS diagnosis was significantly associated with rate of progression and survival. This raises the possibility that early changes in BMI may identify patients likely to have a more malignant course of the disease. However, further research is needed to clarify the relationship between BMI and ALS.


Alzheimers & Dementia | 2012

Medical and environmental risk factors associated with frontotemporal dementia: A case-control study in a veteran population

Yogeshwar V. Kalkonde; Ali Jawaid; Salah U. Qureshi; Peyman Shirani; Michael Wheaton; Gineth P. Pinto-Patarroyo; Paul E. Schulz

Compared with other major dementias, very little is known about the medical and environmental risk factors associated with frontotemporal dementia (FTD). In this study, we evaluated medical and environmental disorders associated with FTD in a veteran population.


Journal of Geriatric Psychiatry and Neurology | 2012

Anxiety Disorders, Physical Illnesses, and Health Care Utilization in Older Male Veterans With Parkinson Disease and Comorbid Depression

Salah U. Qureshi; Amber B. Amspoker; Jessica Calleo; Mark E. Kunik; Laura Marsh

This study examined the rates of anxiety and depressive disorders, physical illnesses, and health service use in male patients 55 years or older with a diagnosis of Parkinson disease who were seen at least twice at the 10 medical centers in the Veterans Affairs Healthcare Network of the South Central region of the United States. Of the 273 male patients diagnosed between October 1, 1997, and September 30, 2009, 62 (22.7%) had a depressive disorder. The overall prevalence of anxiety disorders was 12.8%; patients with comorbid depression had a 5-fold greater prevalence of anxiety disorders than those without depression (35.5% vs 6.2%, P < .0001). Patients with comorbid depression also had increased prevalence of all physical illnesses examined and more outpatient clinic and mental health visits. Patients with Parkinson disease and comorbid depression are more likely to have anxiety disorders and several physical illnesses, to be using antipsychotic and dementia medicines, and to have increased health service utilization than those without depression.


Journal of Neuropsychiatry and Clinical Neurosciences | 2013

Hippocampal Volumes in Patients With Chronic Combat-Related Posttraumatic Stress Disorder: A Systematic Review

Jason E. Childress; Emily McDowell; Venkata Vijaya Kumar Dalai; Saivivek R. Bogale; Chethan Ramamurthy; Ali Jawaid; Mark E. Kunik; Salah U. Qureshi; Paul E. Schulz

The authors and others have recently demonstrated that veterans with chronic combat-related PTSD (CR-PTSD) have a twofold increased risk of dementia. To understand this increased incidence, they performed a systematic review of the literature on neuroanatomical differences between veterans with chronic CR-PTSD and control subjects (22 included studies). The hippocampus was most commonly and consistently reported to differ between groups, thereby suggesting the hypothesis that PTSD is associated with smaller hippocampi, which increases the risk for dementia. However, an alternate hypothesis is that smaller hippocampal volumes are a preexisting risk factor for PTSD and dementia. Studies are clearly needed to differentiate between these important possibilities.


Psychiatric Quarterly | 2012

Is there evidence for late cognitive decline in chronic schizophrenia

Jharna N. Shah; Salah U. Qureshi; Ali Jawaid; Paul E. Schulz

Schizophrenia (SZP) has been historically referred to as “dementia praecox” because of the recognition that its onset is associated with deficits in memory, attention and visuospatial orientation. We wondered whether there is evidence for additional cognitive decline late in the course of chronic SZP. This review examined the evidence (1) for cognitive decline late in the course of chronic SZP, (2) for how often the late cognitive decline occurs, and (3) whether the cognitive decline in late-life SZP is related to pathophysiology of SZP versus the superimposition of another type of dementia. A PUBMED search was performed combining the MESH terms schizophrenia and dementia, cognitive decline, cognitive impairment and cognitive deficits. A manual search of article bibliographies was also performed. We included longitudinal clinical studies employing standard tests of cognition. Cross-sectional studies and those that did not test cognition through standard cognitive tests were excluded. The initial search produced 3898 studies. Employing selection criteria yielded twenty-three studies. Our data extraction tool included the number of patients in the study, whether a control group was present, the age of patients at baseline and follow-up, the study setting (inpatients versus outpatients), the cognitive tests employed, study duration, and results. Only three longitudinal studies tested for dementia using Diagnostic and statistical manual of mental disorder (DSM) or International classification of disease (ICD) criteria and compared them to controls: two studies demonstrated an increase in the prevalence of dementia and one did not. Twenty longitudinal studies tested for one or more cognitive domains without employing standard criteria for dementia: twelve studies demonstrated a heterogeneous pattern of cognitive decline and eight did not. Studies generally did not control for known risk factors for cognitive impairment such as education, vascular risk factors, apolipoprotein (ApoE) genotype and family history. The evidence for late cognitive decline in SZP is mixed, but, slightly more studies suggest that it occurs. If it occurs, it is unclear whether it is related to SZP or other risks for cognitive impairment. Hence, prospective, longitudinal, controlled studies are needed to confirm that there is progressive cognitive decline in chronic SZP which occurs independent of other risk factors for cognitive impairment.


European Journal of Neurology | 2011

Does apolipoprotein E genotype modify the clinical expression of ALS

Ali Jawaid; M. Poon; Adriana M. Strutt; L. K. Rice; Emily McDowell; Alicia R. Salamone; Salah U. Qureshi; Ericka Simpson; Stanley H. Appel; Michele K. York; Paul E. Schulz

Background:  The presence of the apolipoprotein E (ApoE) 4 genotype is associated with an earlier age of onset for Alzheimer’s disease (AD) and several other neurodegenerative disorders. The objective of this study was to investigate the effect of ApoE genotypes on the clinical course of amyotrophic lateral sclerosis (ALS).

Collaboration


Dive into the Salah U. Qureshi's collaboration.

Top Co-Authors

Avatar

Paul E. Schulz

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark E. Kunik

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jeffrey M. Pyne

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Kathy M. Magruder

Medical University of South Carolina

View shared research outputs
Top Co-Authors

Avatar

Andrew M. Wilson

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Teresa J. Hudson

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Adriana M. Strutt

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Emily McDowell

Baylor College of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge